IRF4 mutations in chronic lymphocytic leukemia
Authors:
- 8 September 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 118 (10) , 2827-2829
Abstract
Interferon regulatory factor 4 (IRF4) is a member of the interferon regulatory factor family of transcription factors and has been shown to have critical functions at several stages of B-cell development. Genome-wide association study identified a polymorphism in the 3′ untranslated region of IRF4 as a chronic lymphocytic leukemia risk locus. In this study, we report a recurrent heterozygous somatic mutation in the DNA-binding domain of IRF4 detected in 7 of 457 chronic lymphocytic leukemia patients (1.5%). Patients with IRF4 mutation have a good prognosis, and 4 of 6 have a trisomy 12. We also found that IRF4 mRNA expression is higher in the patients with the mutation.Keywords
This publication has 16 references indexed in Scilit:
- Initial genome sequencing and analysis of multiple myelomaNature, 2011
- IRF4: Immunity. Malignancy! Therapy?Clinical Cancer Research, 2009
- Interferon regulatory factor 4 and 8 in B-cell developmentTrends in Immunology, 2008
- A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemiaNature Genetics, 2008
- IRF4 addiction in multiple myelomaNature, 2008
- Regulation of Lymphocyte Apoptosis by Interferon Regulatory Factor 4 (IRF-4)Journal of Experimental Medicine, 2003
- Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemiaBlood, 2002
- Genomic Aberrations and Survival in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte FunctionScience, 1997
- Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator.Genes & Development, 1995